CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Chris Peetz

Chief Executive Officer, Mirum

Search every verified Chris Peetz interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Chris Peetz, chief executive officer of Mirum Pharmaceuticals, discussed the company's fourth-quarter and full-year 2025 financial results during a February 2026 earnings call, noting that growth was primarily driven by Livmarli sales and that the company anticipated lower revenues from Japan in the upcoming year due to prior inventory buildup. He also addressed the competitive landscape for hepatitis delta virus (HDV) treatments, stating that while no therapy is specifically labeled in the U.S. and one medicine, Hepcludex, is approved in Europe, the field is expected to evolve with potential U.S. approvals and other investigational regimens. In December 2025, Peetz announced Mirum's definitive agreement to acquire Bluejay Therapeutics, adding berlobivug, an anti-hepatitis B surface antigen monoclonal antibody for chronic hepatitis delta, to the company's pipeline. He projected that the majority of peak sales for the product would come from the U.S., estimating roughly 2,000 to 3,000 patients treated chronically at peak. During an August 2025 earnings call, Peetz highlighted the company's momentum, citing three approved medicines with reimbursed patients in over 30 countries and a pipeline advancing toward multiple pivotal studies. He also discussed the commercial expansion of Livmarli, attributing growth to increased awareness of genetic testing and later-onset PFIC diagnoses, and noted plans for a PSC launch in 2027.

Recent appearances

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →